Online inquiry

IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14791MR)

This product GTTS-WQ14791MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Multiple myeloma (MM), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14791MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8775MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ12550MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ3926MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ13252MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ11976MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ5863MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ12191MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ13708MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW